Chemomab Therapeutics annual net debt
2018
2019
2020
2021
2022
2023
2024
2025
Chemomab Therapeutics Net Debt Growth & History (CMMB)
Chemomab Therapeutics's net debt was −$7.6M for fiscal 2025.
View full Chemomab Therapeutics company overviewChemomab Therapeutics annual net debt history
| Fiscal year | Period ended | Net debt | Change | Growth |
|---|---|---|---|---|
| 2025 | 2025-12-31 | −$7.6M | −$1.8M | — |
| 2024 | 2024-12-31 | −$5.7M | $3.2M | — |
| 2023 | 2023-12-31 | −$8.9M | $4.4M | — |
| 2022 | 2022-12-31 | −$13.3M | $1.5M | — |
| 2021 | 2021-12-31 | −$14.8M | −$3.4M | — |
| 2020 | 2020-12-31 | −$11.5M | $5.0M | — |
| 2019 | 2019-12-31 | −$16.5M | −$10.6M | — |
| 2018 | 2018-12-31 | −$5.8M | — | — |
Chemomab Therapeutics quarterly net debt
Q4.18
Q4.19
Q1.20
Q2.20
Q3.20
Q4.20
Q1.21
Q2.21
Q3.21
Q4.21
Q1.22
Q2.22
Q3.22
Q4.22
Q1.23
Q2.23
Q4.23
Q2.24
Q4.24
Q1.25
Q2.25
Q3.25
Q4.25
| Fiscal quarter | Period ended | Net debt | Change | YoY change |
|---|---|---|---|---|
| Q4 2025 | 2025-12-31 | −$7.6M | −$1.8M | — |
| Q3 2025 | 2025-09-30 | −$7.0M | — | — |
| Q2 2025 | 2025-06-30 | −$5.4M | −$772,000 | — |
| Q1 2025 | 2025-03-31 | −$8.0M | — | — |
| Q4 2024 | 2024-12-31 | −$5.7M | $3.2M | — |
| Q2 2024 | 2024-06-30 | −$4.7M | $5.6M | — |
| Q4 2023 | 2023-12-31 | −$8.9M | $4.4M | — |
| Q2 2023 | 2023-06-30 | −$10.2M | −$638,000 | — |
| Q1 2023 | 2023-03-31 | −$20.6M | −$7.1M | — |
| Q4 2022 | 2022-12-31 | −$13.3M | $1.5M | — |
| Q3 2022 | 2022-09-30 | −$10.5M | $26.9M | — |
| Q2 2022 | 2022-06-30 | −$9.6M | $35.4M | — |
| Q1 2022 | 2022-03-31 | −$13.5M | $44.3M | — |
| Q4 2021 | 2021-12-31 | −$14.8M | −$3.4M | — |
| Q3 2021 | 2021-09-30 | −$37.4M | −$30.9M | — |
| Q2 2021 | 2021-06-30 | −$45.0M | −$36.5M | — |
| Q1 2021 | 2021-03-31 | −$57.8M | −$44.1M | — |
| Q4 2020 | 2020-12-31 | −$11.5M | $5.0M | — |
| Q3 2020 | 2020-09-30 | −$6.5M | — | — |
| Q2 2020 | 2020-06-30 | −$8.5M | — | — |
| Q1 2020 | 2020-03-31 | −$13.7M | — | — |
| Q4 2019 | 2019-12-31 | −$16.5M | −$10.6M | — |
| Q4 2018 | 2018-12-31 | −$5.8M | — | — |
Chemomab Therapeutics net debt trends
Over the last five fiscal years, Chemomab Therapeutics's net debt increased from −$11.5M to −$7.6M, a change of $3.9M. The latest reported quarter, Q4 2025, shows −$7.6M.
About the metric
What net debt means
Net debt compares a company’s interest-bearing debt with its cash and cash equivalents. Positive net debt means debt exceeds cash, while a negative value indicates the company has more cash than debt on this measure.
Calculation and source
How net debt is calculated
TickerStat calculates net debt as total interest-bearing debt minus cash and cash equivalents at the same reporting-period end. Short-term investments are not subtracted because they are not included in the standardized cash series. Fiscal periods can differ from calendar years, so exact period-end dates are included.
Review Chemomab Therapeutics source filings ↗